Publicacións nas que colabora con Javier Cortés Castán (6)

2023

  1. XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

    Breast Cancer Research, Vol. 25, Núm. 1

2022

  1. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  2. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2018

  1. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

    Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829

2017

  1. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

2014

  1. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 32, pp. 3626-3634